Shenzhen Second People's Hospital
深圳市第二人民医院
Listed for 15 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Shenzhen Second People's Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌4 papers led
- Hepatocellular carcinoma肝细胞癌17 papers led
- Stomach cancer胃癌14 papers led
- Retinoblastoma视网膜母细胞瘤2 papers led
- Chordoma脊索瘤1 paper led
- Osteosarcoma骨肉瘤3 papers led
- Neuroblastoma神经母细胞瘤0 papers led
- Multiple myeloma多发性骨髓瘤2 papers led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led
- Beta thalassaemiaβ 地中海贫血2 papers led
- Haemophilia A血友病 A0 papers led
- Wilson disease肝豆状核变性(Wilson 病)3 papers led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎1 paper led
- Alport syndromeAlport 综合征1 paper led
- IgA nephropathyIgA 肾病3 papers led
Not listed for: Oesophageal squamous cell carcinoma, Hepatoblastoma, Gastrointestinal stromal tumour, Ewing sarcoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 4 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
8 hospitals in Shenzhen for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingAdjuvant vs Surgery Only in Early-stage Recurrent NPC
- Phase
- Phase 3
- Started
- 2024-06
- Registry
- NCT06228079
Age 18 years to 75 years (registered criteria)
Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen
- RecruitingNeoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
- Phase
- Phase 3
- Started
- 2024-07
- Registry
- NCT06235203
Age 18 years to 75 years (registered criteria)
Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led4
- Integrated Analysis of the LncRNA-Mediated ceRNA Network Associated With Prognosis in Posttreatment Recurrent Nasopharyngeal Carcinoma.
- TMEM52B Isoforms P18 and P20 Differentially Promote the Oncogenesis and Metastasis of Nasopharyngeal Carcinoma.
- Diagnosis of nasopharyngeal carcinoma using an ultrasensitive immunoassay method based on nanoparticles.
- FGF-2 signaling in nasopharyngeal carcinoma modulates pericyte-macrophage crosstalk and metastasis.
All its trials on ClinicalTrials.gov, any status4
More papers found outside PubMed (not counted)3
- EGFR-Regulated EMT is a Driver of Vasculogenic Mimicry in Nasopharyngeal Carcinoma
- Rapid and sensitive detection of Epstein-Barr virus antibodies in nasopharyngeal carcinoma by chemiluminescence strips based on iron-porphyrin single atom nanozyme
- Primary or Metastatic Encephaloma Presenting as a Spontaneous Extradural Hematoma
Cancer
Hepatocellular carcinoma
肝细胞癌Led 17 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Shenzhen for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led17
- Membranous Staining of CD10 Is Related to Steatosis Changes in Hepatocellular Carcinoma: An Investigation of CD10 Stainning in Hepatocellular Carcinoma, Focal Nodular Hyperplasia, and Intrahepatic Cholangiocarcinoma.
- NSUN6 Maintains BMPER Stability in an m5C-Dependent Manner to Suppress Cell Proliferation and Migration in Hepatocellular Carcinoma.
- Adverse events associated with hepatic arterial infusion chemotherapy and its combination therapies in hepatocellular carcinoma: a systematic review.
- Tissue Factor Pathway Inhibitor 2 Enhances Hepatocellular Carcinoma Chemosensitivity by Activating CCAR2-GADD45A-Mediated DNA Damage Repair.
- UiO-66-NH2 Dispersed Solid-Phase Extraction Combined With Liquid Chromatography-Tandem Mass Spectrometry for Metabolomics Analysis in Cancer Patients and Healthy Individuals.
- CircSCMH1 Accelerates Sorafenib Resistance in Hepatocellular Carcinoma by Regulating HN1 Expression via miR-485-5p.
- Comparative analysis of the performance of hepatobiliary agents in depicting MRI features of microvascular infiltration in hepatocellular carcinoma.
- TRPM8 overexpression suppresses hepatocellular carcinoma progression and improves survival by modulating the RTP3/STAT3 pathway.
- Comparison of the Ability of Gadobenate Dimeglumine and Gadolinium Ethoxybenzyl Dimeglumine to Display the major Features for Noninvasively Diagnosing Hepatocellular Carcinoma According to the LI-RADS 2018v.
- MiR-375 attenuates sorafenib resistance of hepatocellular carcinoma cells by inhibiting cell autophagy.
- Asymmetric total synthesis and anti-hepatocellular carcinoma profile of enantiopure euphopilolide and jolkinolide E.
- Human liver cancer organoids: Biological applications, current challenges, and prospects in hepatoma therapy.
- Construction of a lipid metabolism-related risk model for hepatocellular carcinoma by single cell and machine learning analysis.
- Construction of endothelial cell-related and autophagy-related prognostic models for hepatocellular carcinoma based on single-cell data.
- Clinical and Prognostic Value of PPIA, SQSTM1, and CCL20 in Hepatocellular Carcinoma Patients by Single-Cell Transcriptome Analysis.
- DDX56 transcriptionally activates MIST1 to facilitate tumorigenesis of HCC through PTEN-AKT signaling.
- Preparation of PLGA microspheres loaded with 10-hydroxycamptothecin and arsenic trioxide and their treatment for rabbit hepatocellular carcinoma.
Cancer
Stomach cancer
胃癌Led 14 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Shenzhen for stomach cancer218 hospitals in China for stomach cancer
No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led14
- Efficient synthesis of new isopavine alkaloids derived from (-)-reframidine and evaluation of their anti-proliferative effect against gastric cancer cells.
- Epigallocatechin Gallate Induces miR-192/215 Suppression of EGR1 in Gastric Cancer.
- Gastric cardiac leiomyoma complicated with massive gastrointestinal bleeding: A rare case report.
- Endoscopic submucosal excavation for gastric muscularis propria tumours less than 10 mm in diameter: What are the risk factors responsible for perforation?
- Efficacy and safety of ESR-EB and ESE in the treatment of small gastric muscularis propria tumours: single-centre prospective cohort study.
- Gastric inflammatory myofibroblastic tumor invading the esophagus and spleen: a rare case report and literature review.
- Giant gastric leiomyoma excision using endoscopic submucosal dissection with dental floss clip traction technique: a case report.
- Preliminary differentiation of benign and malignant gastric wall thickening using dual-layer spectral-detector CT.
- Streptococcus anginosus: A new pathogen of superficial gastritis, atrophic gastritis and gastric cancer.
- CircNRD1 elevates THAP domain containing 11 through sequestering microRNA-421 to inhibit gastric cancer growth and tumorigenesis.
- The application and effect of presuturing with clips in endoscopic full-thickness resection.
- A multicentre, prospective cohort study comparing two endoscopic procedures for the treatment of gastric muscularis propria lesions.
- Early oesophageal carcinoma with a defect of the oesophageal muscularis propria: a rare case report.
- Improved profiling of low molecular weight serum proteome for gastric carcinoma by data-independent acquisition.
Cancer
Retinoblastoma
视网膜母细胞瘤Led 2 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Shenzhen for retinoblastoma196 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Cancer
Chordoma
脊索瘤Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Shenzhen for chordoma88 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Osteosarcoma
骨肉瘤Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
23 hospitals in Shenzhen for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
Cancer
Neuroblastoma
神经母细胞瘤Led no English-language PubMed papers on neuroblastoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Shenzhen for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 2 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.1%.
- Open trials led
- 0
- recruiting or about to
5 hospitals in Shenzhen for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2023-10
- Registry
- NCT06049290
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Phase
- Phase 3
- Started
- 2021-10
- Registry
- NCT05020236
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status9
- Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma
- T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
- A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
- A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
- A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
- APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Shenzhen for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia
No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Beta thalassaemia
β 地中海贫血Led 2 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
7 hospitals in Shenzhen for beta thalassaemia157 hospitals in China for beta thalassaemia
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
- Phase
- Phase 2
- Started
- 2019-11
- Registry
- NCT04143724
Age 6 years to 17 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Guangzhou, Nanning, Shenzhen
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Haemophilia A
血友病 ALed no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Shenzhen for haemophilia A160 hospitals in China for haemophilia A
No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status5
- Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor
- A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
- Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
- Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor
- ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)
Other diseases
Wilson disease
肝豆状核变性(Wilson 病)Led 3 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 1.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Shenzhen for Wilson disease28 hospitals in China for Wilson disease
No open trial on Wilson disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led3
- Clinical significance of platelet-to-white blood cell ratio in patients with Wilson disease: a retrospective cohort study.
- Exploring the impact of gut microbiota on liver health in mice and patients with Wilson disease.
- Anemia Is Associated with Disease Severity, Hepatic Complications, and Progression of Wilson Disease: A Retrospective Cohort Study.
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 1 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Shenzhen for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Alport syndrome
Alport 综合征Led 1 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 1.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Shenzhen for Alport syndrome60 hospitals in China for Alport syndrome
No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other diseases
IgA nephropathy
IgA 肾病Led 3 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.4%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Shenzhen for IgA nephropathy346 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Incidence and pathological features of IgA nephropathy before and during the COVID-19 pandemic.
- A mixed-method evaluation of the relationship between Oxford classification scores and longitudinal changes in proteinuria in patients with immunoglobulin A nephropathy.
- The increased miRNA-150-5p expression of the tonsil tissue in patients with IgA nephropathy may be related to the pathogenesis of disease.
Earlier papers (2016–2020)2
Getting in touch
Name card to show staff or a driver
深圳市第二人民医院
Shenzhen Second People's Hospital
深圳
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
First Affiliated Hospital of Shenzhen University; Biobank of Shenzhen Second People's Hospital; Bio-Bank of Shenzhen Second People's Hospital; Shenzhen Second People Hospital; First Affiliated Hospital of Shenzhen University Health Science Center; Shenzhen University First Affiliated Hospital